/5
0 avis
FFCD Prodige 31 Reminnet. FFCD Prodige 31 Reminnet: a european, multicentre, phase II/III randomized double-blind, placebo-controlled study evaluating. : lanreotide as maintenance therapy after first-line (1l) treatment in patients with non-resectableduodeno-pancreatic neuroendocrine
Archive ouverte
Edité par CCSD -
International audience
Consulter en ligne
Chargement des enrichissements...